1,028 results on '"Michael Fried"'
Search Results
2. Conversation in Lisbon University
- Author
-
Michael Fried
- Subjects
Arts in general ,NX1-820 ,Museums. Collectors and collecting ,AM1-501 ,Latin America. Spanish America ,F1201-3799 - Published
- 2021
- Full Text
- View/download PDF
3. Effects of hunger on mood and affect reactivity to monetary reward in women with obesity - A pilot study.
- Author
-
Mayron Piccolo, Gabriella Milos, Sena Bluemel, Sonja Schumacher, Christoph Müller-Pfeiffer, Michael Fried, Monique Ernst, and Chantal Martin-Soelch
- Subjects
Medicine ,Science - Abstract
Worldwide, nearly 3 million people die every year because of being overweight or obese. Although obesity is a metabolic disease, behavioral aspects are important in its etiology. Hunger changes the rewarding potential of food in normal-weight controls. In obesity, impairments related to reward processing are present, but it is not clear whether these are due to mental disorders more common among this population. Therefore, in this pilot study, we aimed at investigating whether fasting influence mood reactivity to reward in people with obesity. Women with obesity (n = 11, all mentally healthy) and normal weight controls (n = 17) were compared on a computerized monetary reward task (the wheel of fortune), using self-reports of mood and affect (e.g., PANAS and mood evaluation during the task) as dependent variables. This task was done in 2 satiety conditions, during fasting and after eating. Partially, in line with our expectation of a reduced affect and mood reactivity to monetary reward in participants with obesity accentuated by fasting, our results indicated a significant within-group difference across time (before and after the task), with monetary gains significantly improving positive affect in healthy controls (p>0.001), but not in individuals with obesity (p = 0.32). There were no significant between-group differences in positive affect before (p = 0.328) and after (p = 0.70) the task. In addition, women with obesity, compared to controls, reported more negative affect in general (p < 0.05) and less mood reactivity during the task in response to risky gains (p < 0.001) than healthy controls. The latter was independent of the level of satiety. These preliminary results suggest an impairment in mood reactivity to monetary reward in women with obesity which is not connected to the fasting state. Increasing the reinforcing potential of rewards other than food in obesity may be one target of intervention in order to verify if that could reduce overeating.
- Published
- 2020
- Full Text
- View/download PDF
4. PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer
- Author
-
Marianne R. Spalinger, Roberto Manzini, Larissa Hering, Julianne B. Riggs, Claudia Gottier, Silvia Lang, Kirstin Atrott, Antonia Fettelschoss, Florian Olomski, Thomas M. Kündig, Michael Fried, Declan F. McCole, Gerhard Rogler, and Michael Scharl
- Subjects
inflammasome ,TC-PTP ,inflammatory bowel disease ,IBD ,colitis ,interleukin-1-alpha ,Biology (General) ,QH301-705.5 - Abstract
Summary: Variants in the gene locus encoding protein tyrosine phosphatase non-receptor type 2 (PTPN2) are associated with inflammatory disorders, including inflammatory bowel diseases, rheumatoid arthritis, and type 1 diabetes. The anti-inflammatory role of PTPN2 is highlighted by the fact that PTPN2-deficient mice die a few weeks after birth because of systemic inflammation and severe colitis. However, the tissues, cells, and molecular mechanisms that contribute to this phenotype remain unclear. Here, we demonstrate that myeloid cell-specific deletion of PTPN2 in mice (PTPN2-LysMCre) promotes intestinal inflammation but protects from colitis-associated tumor formation in an IL-1β-dependent manner. Elevated levels of mature IL-1β production in PTPN2-LysMCre mice are a consequence of increased inflammasome assembly due to elevated phosphorylation of the inflammasome adaptor molecule ASC. Thus, we have identified a dual role for myeloid PTPN2 in directly regulating inflammasome activation and IL-1β production to suppress pro-inflammatory responses during colitis but promote intestinal tumor development.
- Published
- 2018
- Full Text
- View/download PDF
5. Behavioral Responses to Uncertainty in Weight-Restored Anorexia Nervosa – Preliminary Results
- Author
-
Mayron Piccolo, Gabriella Franca Milos, Sena Bluemel, Sonja Schumacher, Christoph Mueller-Pfeiffer, Michael Fried, Monique Ernst, and Chantal Martin-Soelch
- Subjects
anorexia nervosa ,intolerance of uncertainty ,weight-restoration ,longitudinal ,eating disorders ,remission ,Psychology ,BF1-990 - Abstract
Impaired decision-making under conditions of uncertainty seems to contribute to the expression and maintenance of anorexia nervosa (AN), but it is not clear whether this impairment is a disease state that would remit with treatment, or a persisting trait in patients with AN. To examine this question, a longitudinal study was conducted in 12 female inpatients with AN (age M = 22.2, SE = 1.36), before (Time-1) and after reaching a body mass index of >17.5 kg/m2 (Time-2). Intolerance of uncertainty (IU) was assessed via a decision-making task, the wheel of fortune (WOF). Weight gain at Time-2 was accompanied with significant changes in uncertainty-related performance compared to Time-1 [(Time × Uncertainty), p < 0.05]. At Time-1, reaction times (RTs) varied in function of uncertainty, while at Time-2, uncertainty did not modulate RTs. These findings support a change in decision-making under uncertainty with successful weight-rehabilitation in AN. While IU was present in underweight patients, it became non-significant after weight restoration.
- Published
- 2019
- Full Text
- View/download PDF
6. Hypoxia Positively Regulates the Expression of pH-Sensing G-ProteinâCoupled Receptor OGR1 (GPR68)Summary
- Author
-
Cheryl de Vallière, Jesus Cosin-Roger, Simona Simmen, Kirstin Atrott, Hassan Melhem, Jonas Zeitz, Mehdi Madanchi, Irina Tcymbarevich, Michael Fried, Gerd A. Kullak-Ublick, Stephan R. Vavricka, Benjamin Misselwitz, Klaus Seuwen, Carsten A. Wagner, Jyrki J. Eloranta, Gerhard Rogler, and Pedro A. Ruiz
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: A novel family of proton-sensing G-proteinâcoupled receptors, including ovarian cancer G-proteinâcoupled receptor 1 (OGR1) (GPR68) has been identified to play a role in pH homeostasis. Hypoxia is known to change tissue pH as a result of anaerobic glucose metabolism through the stabilization of hypoxia-inducible factor-1α. We investigated how hypoxia regulates the expression of OGR1 in the intestinal mucosa and associated cells. Methods: OGR1 expression in murine tumors, human colonic tissue, and myeloid cells was determined by quantitative reverse-transcription polymerase chain reaction. The influence of hypoxia on OGR1 expression was studied in monocytes/macrophages and intestinal mucosa of inflammatory bowel disease (IBD) patients. Changes in OGR1 expression in MonoMac6 (MM6) cells under hypoxia were determined upon stimulation with tumor necrosis factor (TNF), in the presence or absence of nuclear factor-κB (NF-κB) inhibitors. To study the molecular mechanisms involved, chromatin immunoprecipitation analysis of the OGR1 promoter was performed. Results: OGR1 expression was significantly higher in tumor tissue compared with normal murine colon tissue. Hypoxia positively regulated the expression of OGR1 in MM6 cells, mouse peritoneal macrophages, primary human intestinal macrophages, and colonic tissue from IBD patients. In MM6 cells, hypoxia-enhanced TNF-induced OGR1 expression was reversed by inhibition of NF-κB. In addition to the effect of TNF and hypoxia, OGR1 expression was increased further at low pH. Chromatin immunoprecipitation analysis showed that HIF-1α, but not NF-κB, binds to the promoter of OGR1 under hypoxia. Conclusions: The enhancement of TNF- and hypoxia-induced OGR1 expression under low pH points to a positive feed-forward regulation of OGR1 activity in acidic conditions, and supports a role for OGR1 in the pathogenesis of IBD. Keywords: Ovarian Cancer G-ProteinâCoupled Receptor, Inflammation, Inflammatory Bowel Disease, TDAG8, GRP65
- Published
- 2016
- Full Text
- View/download PDF
7. Zdobycz' Gustava Courbeta (z ekskursem na temat „Śmierci jelenia')
- Author
-
Michael Fried
- Subjects
History of the arts ,NX440-632 ,Visual arts ,N1-9211 - Published
- 2018
- Full Text
- View/download PDF
8. Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation.
- Author
-
Jesus Cosin-Roger, Marianne R Spalinger, Pedro A Ruiz, Claudia Stanzel, Anne Terhalle, Lutz Wolfram, Hassan Melhem, Kirstin Atrott, Silvia Lang, Isabelle Frey-Wagner, Michael Fried, Michael Scharl, Martin Hausmann, and Gerhard Rogler
- Subjects
Medicine ,Science - Abstract
Gp96 is an endoplasmic reticulum chaperone for multiple protein substrates. Its lack in intestinal macrophages of Crohn's disease (CD) patients is correlated with loss of tolerance against the host gut flora. Gp96 has been stablished to be an essential chaperone for Toll-like receptors (TLRs). We studied the impact of gp96-knockdown on TLR-function in macrophages. TLR2 and TLR4 expression was only decreased but not abolished when gp96 was knocked-down in cell lines, whereas in a monocyte/macrophage specific knock-out mouse model (LysMCre) TLR4 was abolished, while TLR2 was still present. Lipopolysaccharide (LPS)-induced NF-κB activation was still observed in the absence of gp96, and gp96-deficient macrophages were able to up-regulate surface TLR4 upon LPS treatment, suggesting that there is another chaperone involved in the folding of TLR4 upon stress responses. Moreover, LPS-dependent pro-inflammatory cytokines were still expressed, although to a lesser extent in the absence of gp96, which reinforces the fact that gp96 is involved in regulating signaling cascades downstream of TLR4 are impaired upon loss of gp96. In addition, we have also found a reduced phosphorylation of ERK and p38 kinases and an impaired response upon CSF1R activation in gp96 deficient macrophages. Our findings indicate that the loss of gp96 not only impairs TLR4 signaling, but is also associated with a diminished phosphorylation of ERK and mitogen-activated stress kinases resulting in an impaired signalling through several receptors, including CSF1R.
- Published
- 2018
- Full Text
- View/download PDF
9. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
- Author
-
Marianne R Spalinger, Jonas Zeitz, Luc Biedermann, Jean-Benoit Rossel, Michael C Sulz, Pascal Frei, Sylvie Scharl, Stephan R Vavricka, Michael Fried, Gerhard Rogler, Michael Scharl, and Swiss IBD Cohort Study Group
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Protein tyrosine phosphatase non-receptor type 22 (PTPN22) plays an important role in immune cell function and intestinal homeostasis. The single nucleotide polymorphism (SNP) rs2476601 within the PTPN22 gene locus results in aberrant function of PTPN22 protein and protects from Crohn's disease (CD). Here, we investigated associations of PTPN22 SNP rs2476601 in inflammatory bowel disease (IBD) patients in the Swiss IBD Cohort Study (SIBDCS). METHODS:2'028 SIBDCS patients (1173 CD and 855 ulcerative colitis (UC) patients) were included. The clinical characteristics were analysed for an association with the presence of the PTPN22 SNP rs2476601 genotypes 'homozygous variant' (AA), 'heterozygous' (GA) and 'homozygous wild-type' (GG). RESULTS:13 patients (0.6%) were homozygous variant (AA) for the PTPN22 polymorphism, 269 (13.3%) heterozygous variant (GA) and 1'746 (86.1%) homozygous wild-type (GG). In CD, AA and GA genotypes were associated with less use of steroids and antibiotics, and reduced prevalence of vitamin D and calcium deficiency. In UC the AA and GA genotype was associated with increased use of azathioprine and anti-TNF antibodies, but significantly less patients with the PTPN22 variant featured malabsorption syndrome (p = 0.026). CONCLUSION:Our study for the first time addressed how presence of SNP rs2476601 within the PTPN22 gene affects clinical characteristics in IBD-patients. Several factors that correlate with more severe disease were found to be less common in CD patients carrying the A-allele, pointing towards a protective role for this variant in affected CD patients. In UC patients however, we found the opposite trend, suggesting a disease-promoting effect of the A-allele.
- Published
- 2016
- Full Text
- View/download PDF
10. Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.
- Author
-
Jonas Zeitz, Melike Ak, Séverine Müller-Mottet, Sylvie Scharl, Luc Biedermann, Nicolas Fournier, Pascal Frei, Valerie Pittet, Michael Scharl, Michael Fried, Gerhard Rogler, Stephan Vavricka, and Swiss IBD Cohort Study Group
- Subjects
Medicine ,Science - Abstract
Pain is a common symptom related to inflammatory bowel disease (IBD). In addition to abdominal pain, pain can also be an extraintestinal manifestation of IBD. Pain treatment is challenging and a substantial part of IBD patients are treated with opioids. Therefore, a better knowledge on pain symptoms is crucial for a better therapeutic approach to this clinical problem.Patients of the Swiss IBD Cohort Study (SIBDCS) (n = 2152) received a questionnaire regarding pain intensity, pain localization and impact of pain on daily life and social activities. Furthermore, the questionnaire investigated the use of pain-specific medication.A vast majority of patients (71%) experienced pain during the disease course. For a substantial part of patients (49% in UC and 55% in CD) pain is a longstanding problem (>5 years). Pain in UC was of shorter duration compared to CD (p < 0.01). Abdominal pain (59.5%) and back pain (38.3%) were the main pain localizations. 67% of patients took pain medication; 24% received no pain treatment. The general quality of life was significantly lower in patients suffering of pain compared to those without pain (38 vs. 77; (-100 very bad; 100 very good) p
- Published
- 2016
- Full Text
- View/download PDF
11. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.
- Author
-
Marius Vögelin, Luc Biedermann, Pascal Frei, Stephan R Vavricka, Sylvie Scharl, Jonas Zeitz, Michael C Sulz, Michael Fried, Gerhard Rogler, and Michael Scharl
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Thiopurines are known to cause lymphopenia (
- Published
- 2016
- Full Text
- View/download PDF
12. Absorto na ação
- Author
-
Michael Fried
- Subjects
Zidane ,retrato ,absorção ,teatralidade ,portrait ,absorption ,theatricality ,Social sciences (General) ,H1-99 - Abstract
O filme Zidane, um retrato do século XXI, de Douglas Gordon e Philippe Parreno (2006) pertence à tradição de absorção que desempenhou um papel crucial na evolução da arte moderna. O autor explora a tensão entre absorção e teatralidade - central tanto para a pintura francesa do século XVIII como para a fotografia dos séculos XX e XXI - e tira conseqüências estéticas e filosóficas do filme que retrata, ao longo de todos os noventa minutos de uma partida de futebol, o meio-campista francês Zinedine Zidane.Zidane, a 21st Century Portrait, a film by Douglas Gordon and Philippe Perreno, belongs to the absorptive tradition that has played a central role in the evolution of modern art. The author explores the tension between absorption and theatricality - crucial to 18th century French art as well as to 20th and 21th century photography - and draws aesthetic and philosophical consequences of this film that depicts, throughout all the 90 minutes of a soccer match, the French midfielder Zinedine Zidane.
- Published
- 2010
- Full Text
- View/download PDF
13. Intensités esthétiques : Flaubert et quelques-uns de ses contemporains
- Author
-
Michael Fried and Jacques Neefs
- Subjects
French literature - Italian literature - Spanish literature - Portuguese literature ,PQ1-3999 - Published
- 2014
14. The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.
- Author
-
Sandra Michaela Frei, Colette Hemsley, Theresa Pesch, Silvia Lang, Achim Weber, Ekkehard Jehle, Anne Rühl, Michael Fried, Gerhard Rogler, and Michael Scharl
- Subjects
Medicine ,Science - Abstract
BACKGROUND: One of the most challenging conditions in Crohn's disease (CD) patients is the treatment of perianal fistulae. We have recently shown that epithelial-to-mesenchymal transition (EMT) plays a crucial role during CD-fistulae development. Dickkopf-homolog 1 (DKK-1) is known to play a key role during EMT. Here, we investigated a role for DKK-1 in the pathogenesis of CD-associated fistulae. METHODS: Dkk-1 protein expression in CD-fistula specimens were investigated by immunohistochemistry. Colonic lamina propria fibroblasts (CLPF) were obtained from either non-IBD control patients or patients with fistulizing CD. HT-29 intestinal epithelial cells (IEC) were either grown as monolayers or spheroids. Cells were treated with either TNF-α, TGF-β or IL-13. Knock-down of DKK-1 or β-Catenin was induced in HT-29-IEC by siRNA technique. mRNA expression was determined by real-time-PCR. RESULTS: Dkk-1 protein was specifically expressed in transitional cells lining the fistula tracts. TGF-β induced DKK-1 mRNA expression in HT-29-IEC, but decreased it in fistula CLPF. On a functional level, DKK-1 knock-down prevented TGF-β-induced IL-13 mRNA expression in HT-29-IEC. Further, loss of β-Catenin was accompanied by reduced levels of DKK-1 and, again, IL-13 in IEC in response to TGF-β. In turn, treatment of HT-29-IEC as well as fistula CLPF with IL-13 resulted in decreased levels of DKK-1 mRNA. Treatment with TNF-α or the bacterial wall component, muramyl-dipeptide, decreased DKK-1 mRNA levels in HT-29-IEC, but enhanced it in fistula CLPF. DISCUSSION: We demonstrate that DKK-1 is strongly expressed in cells lining the CD-fistula tracts and regulates factors involved in EMT initiation. These data provide evidence for a role of DKK-1 in the pathogenesis of CD-associated perianal fistulae.
- Published
- 2013
- Full Text
- View/download PDF
15. Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis.
- Author
-
Belén Morón, Marianne Spalinger, Stephanie Kasper, Kirstin Atrott, Isabelle Frey-Wagner, Michael Fried, Declan F McCole, Gerhard Rogler, and Michael Scharl
- Subjects
Medicine ,Science - Abstract
Spermidine is a dietary polyamine that is able to activate protein tyrosine phosphatase non-receptor type 2 (PTPN2). As PTPN2 is known to be a negative regulator of interferon-gamma (IFN-γ)-induced responses, and IFN-γ stimulation of immune cells is a critical process in the immunopathology of inflammatory bowel disease (IBD), we wished to explore the potential of spermidine for reducing pro-inflammatory effects in vitro and in vivo.Human THP-1 monocytes were treated with IFN-γ and/or spermidine. Protein expression and phosphorylation were analyzed by Western blot, cytokine expression by quantitative-PCR, and cytokine secretion by ELISA. Colitis was induced in mice by dextran sodium sulfate (DSS) administration. Disease severity was assessed by recording body weight, colonoscopy and histology.Spermidine increased expression and activity of PTPN2 in THP-1 monocytes and reduced IFN-γ-induced phosphorylation of signal transducer and activator of transcription (STAT) 1 and 3, as well as p38 mitogen-activated protein kinase (MAPK) in a PTPN2 dependent manner. Subsequently, IFN-γ-induced expression/secretion of intracellular cell adhesion molecule (ICAM)-1 mRNA, monocyte chemoattractant protein (MCP)-1, and interleukin (IL)-6 was reduced in spermidine-treated cells. The latter effects were absent in PTPN2-knockdown cells. In mice with DSS-induced colitis, spermidine treatment resulted in ameliorated weight loss and decreased mucosal damage indicating reduced disease severity.Activation of PTPN2 by spermidine ameliorates IFN-γ-induced inflammatory responses in THP-1 cells. Furthermore, spermidine treatment significantly reduces disease severity in mice with DSS-induced colitis; hence, spermidine supplementation and subsequent PTPN2 activation may be helpful in the treatment of chronic intestinal inflammation such as IBD.
- Published
- 2013
- Full Text
- View/download PDF
16. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans.
- Author
-
Luc Biedermann, Jonas Zeitz, Jessica Mwinyi, Eveline Sutter-Minder, Ateequr Rehman, Stephan J Ott, Claudia Steurer-Stey, Anja Frei, Pascal Frei, Michael Scharl, Martin J Loessner, Stephan R Vavricka, Michael Fried, Stefan Schreiber, Markus Schuppler, and Gerhard Rogler
- Subjects
Medicine ,Science - Abstract
BACKGROUND: The human intestinal microbiota is a crucial factor in the pathogenesis of various diseases, such as metabolic syndrome or inflammatory bowel disease (IBD). Yet, knowledge about the role of environmental factors such as smoking (which is known to influence theses aforementioned disease states) on the complex microbial composition is sparse. We aimed to investigate the role of smoking cessation on intestinal microbial composition in 10 healthy smoking subjects undergoing controlled smoking cessation. METHODS: During the observational period of 9 weeks repetitive stool samples were collected. Based on abundance of 16S rRNA genes bacterial composition was analysed and compared to 10 control subjects (5 continuing smokers and 5 non-smokers) by means of Terminal Restriction Fragment Length Polymorphism analysis and high-throughput sequencing. RESULTS: Profound shifts in the microbial composition after smoking cessation were observed with an increase of Firmicutes and Actinobacteria and a lower proportion of Bacteroidetes and Proteobacteria on the phylum level. In addition, after smoking cessation there was an increase in microbial diversity. CONCLUSIONS: These results indicate that smoking is an environmental factor modulating the composition of human gut microbiota. The observed changes after smoking cessation revealed to be similar to the previously reported differences in obese compared to lean humans and mice respectively, suggesting a potential pathogenetic link between weight gain and smoking cessation. In addition they give rise to a potential association of smoking status and the course of IBD.
- Published
- 2013
- Full Text
- View/download PDF
17. Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy.
- Author
-
Marianne R Spalinger, Silvia Lang, Stephan R Vavricka, Michael Fried, Gerhard Rogler, and Michael Scharl
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Variations within the gene locus encoding protein tyrosine phosphatase non-receptor type 22 (PTPN22) are associated with the risk to develop inflammatory bowel disease (IBD). PTPN22 is involved in the regulation of T- and B-cell receptor signaling, but although it is highly expressed in innate immune cells, its function in other signaling pathways is less clear. Here, we study whether loss of PTPN22 controls muramyl-dipeptide (MDP)-induced signaling and effects in immune cells. MATERIAL & METHODS: Stable knockdown of PTPN22 was induced in THP-1 cells by shRNA transduction prior to stimulation with the NOD2 ligand MDP. Cells were analyzed for signaling protein activation and mRNA expression by Western blot and quantitative PCR; cytokine secretion was assessed by ELISA, autophagosome induction by Western blot and immunofluorescence staining. Bone marrow derived dendritic cells (BMDC) were obtained from PTPN22 knockout mice or wild-type animals. RESULTS: MDP-treatment induced PTPN22 expression and activity in human and mouse cells. Knockdown of PTPN22 enhanced MDP-induced activation of mitogen-activated protein kinase (MAPK)-isoforms p38 and c-Jun N-terminal kinase as well as canonical NF-κB signaling molecules in THP-1 cells and BMDC derived from PTPN22 knockout mice. Loss of PTPN22 enhanced mRNA levels and secretion of interleukin (IL)-6, IL-8 and TNF in THP-1 cells and PTPN22 knockout BMDC. Additionally, loss of PTPN22 resulted in increased, MDP-mediated autophagy in human and mouse cells. CONCLUSIONS: Our data demonstrate that PTPN22 controls NOD2 signaling, and loss of PTPN22 renders monocytes more reactive towards bacterial products, what might explain the association of PTPN22 variants with IBD pathogenesis.
- Published
- 2013
- Full Text
- View/download PDF
18. Regulation of the expression of chaperone gp96 in macrophages and dendritic cells.
- Author
-
Lutz Wolfram, Anne Fischbeck, Isabelle Frey-Wagner, Kacper A Wojtal, Silvia Lang, Michael Fried, Stephan R Vavricka, Martin Hausmann, and Gerhard Rogler
- Subjects
Medicine ,Science - Abstract
The chaperone function of the ER-residing heat shock protein gp96 plays an important role in protein physiology and has additionally important immunological functions due to its peptide-binding capacity. Low amounts of gp96 stimulate immunity; high quantities induce tolerance by mechanisms not fully understood. A lack of gp96 protein in intestinal macrophages (IMACs) from Crohn`s disease (CD) patients correlates with loss of tolerance against the host gut flora, leading to chronic inflammation. Since gp96 shows dose-dependent direction of immunological reactions, we studied primary IMACs and developed cell models to understand the regulation of gp96 expression. Induction of gp96-expression was higher in in vitro differentiated dendritic cells (i.v.DCs) than in in vitro differentiated macrophages (i.v.MACs), whereas monocytes (MOs) expressed only low gp96 levels. The highest levels of expression were found in IMACs. Lipopolysaccharide (LPS), muramyl dipeptide (MDP), tumour necrosis factor (TNF), and Interleukin (IL)-4 induced gp96-expression, while IL12, IL-17, IL-23 and interferon (IFN)-γ were not effective indicating that Th1 and Th17 cells are probably not involved in the induction of gp96. Furthermore, gp96 was able to induce its own expression. The ER-stress inducer tunicamycin increased gp96-expression in a concentration- and time-dependent manner. Both ulcerative colitis (UC) and CD patients showed significantly elevated gp96 mRNA levels in intestinal biopsies which correlated positively with the degree of inflammation of the tissue. Since gp96 is highly expressed on the one hand upon stress induction as during inflammation and on the other hand possibly mediating tolerance, these results will help to understand the whether gp96 plays a role in the pathophysiology of inflammatory bowel disease (IBD).
- Published
- 2013
- Full Text
- View/download PDF
19. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.
- Author
-
Kacper A Wojtal, Gerhard Rogler, Michael Scharl, Luc Biedermann, Pascal Frei, Michael Fried, Achim Weber, Jyrki J Eloranta, Gerd A Kullak-Ublick, and Stephan R Vavricka
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Tumor necrosis factor (TNF) is an important cytokine in the pathogenesis of inflammatory bowel disease (IBD). Anti-TNF antibodies have been successfully implemented in IBD therapy, however their efficacies differ among IBD patients. Here we investigate the influence of CD64 Fc receptor on the inhibitory activity of anti-TNFs in cells of intestinal wall. METHODS: Intestinal cell lines, monocytes/macrophages and peripheral blood mononuclear cells (PBMCs) were used as models. The efficacies of adalimumab, infliximab and certolizumab-pegol were assessed by RT-PCR for target genes. Protein levels and localizations were examined by Western blotting and immunofluorescence. Antibody fragments were obtained by proteolytic digestion, immunoprecipitation and protein chip analysis. Knock-down of specific gene expression was performed using siRNAs. RESULTS: Infliximab had limited efficacy towards soluble TNF in cell types expressing Fc gamma receptor CD64. Both adalimumab and infliximab had lower efficacies in PBMCs of IBD patients, which express elevated levels of CD64. Infliximab-TNF complexes were more potent in activating CD64 in THP-1 cells than adalimumab, which was accompanied by distinct phospho-tyrosine signals. Blocking Fc parts and isolation of Fab fragments of infliximab improved its efficacy. IFN-γ-induced expression of CD64 correlated with a loss of efficacy of infliximab, whereas reduction of CD64 expression by either siRNA or PMA treatment improved inhibitory activity of this drug. Colonic mRNA expression levels of CD64 and other Fc gamma receptors were significantly increased in the inflamed tissues of infliximab non-responders. CONCLUSIONS: CD64 modulates the efficacy of infliximab both in vitro and ex vivo, whereas the presence of this receptor has no impact on the inhibitory activity of certolizumab-pegol, which lacks Fc fragment. These data could be helpful in both predicting and evaluating the outcome of anti-TNF therapy in IBD patients with elevated systemic and local levels of Fc receptors.
- Published
- 2012
- Full Text
- View/download PDF
20. Absorption and Theatricality: Painting and Beholder in the Age of Diderot
- Author
-
Michael Fried
- Published
- 2023
21. The Moment of Caravaggio
- Author
-
Michael Fried
- Published
- 2023
22. Mathematik für Ingenieure II für Dummies
- Author
-
J. Michael Fried
- Published
- 2022
23. French Suite: A Book of Essays
- Author
-
Michael Fried
- Published
- 2022
24. Thomas Demand e suas alegorias da intenção; 'exclusão' em Candida Höfer, Hiroshi Sugimoto, e Thomas Struth
- Author
-
Michael Fried
- Subjects
fotografia contemporânea ,antiteatralidade ,absorção ,teoria da arte ,Michael Fried ,Fine Arts ,Arts in general ,NX1-820 - Abstract
Resumo Em 2008, com a publicação de Why photography matters as art as never before, Michael Fried retoma as discussões iniciadas em “Arte e objetidade”, ensaio de 1967, em especial a ideia de "absorção" ou antiteatralidade da arte, suposta característica da arte modernista em contraposição à minimalista/literalista. Fried debate a questão da "presença", argumentando em prol da antiteatralidade, considerando a "absorção" como a principal qualidade nos trabalhos fotográficos de Thomas Struth, Thomas Demand, Candida Höfer entre outros, sobretudo no capítulo 9, aqui traduzido. A partir de uma minuciosa descrição e da análise formal das imagens, Fried encontra parâmetros para consolidar seu principal argumento: a capacidade de "absorção" da fotografias.
- Full Text
- View/download PDF
25. A Benchmark Corpus of English Misspellings and a Minimally-supervised Model for Spelling Correction.
- Author
-
Michael Flor, Michael Fried, and Alla Rozovskaya
- Published
- 2019
- Full Text
- View/download PDF
26. Painting with Demons: The Art of Gerolamo Savoldo
- Author
-
Michael Fried
- Published
- 2020
27. El lugar del espectador: Estética y orígenes de la pintura moderna
- Author
-
Michael Fried
- Published
- 2019
28. Arte y objetualidad: Ensayos y reseñas
- Author
-
Michael Fried
- Published
- 2018
29. What Was Literary Impressionism?
- Author
-
Michael Fried
- Published
- 2018
30. Editorial
- Author
-
Michael Fried
- Subjects
General Medicine - Published
- 2022
31. Editorial
- Author
-
Michael Fried
- Subjects
General Medicine - Published
- 2023
32. Comparing Oral Medicines to Treat Hepatitis C Virus -- The PRIORITIZE Study
- Author
-
David Nelson, Michael Fried, Mark Sulkowski, Donna Evon, Jodi Segal, Anna Lok, Paul Stewart_ Stewart, Summer Wadsworth Wadsworth, Scott Kixmiller, Anquenette Sloan, Larry Micheal, Meichen Dong, Monika Vainorius, Joy Peter, and Keith Muller
- Published
- 2022
33. La modernidad de Manet: o la superficie de la pintura en la década de 1860
- Author
-
Michael Fried
- Published
- 2015
34. Innovative Endoskopie
- Author
-
Arthur R. Schmidt, Michael Fried, and Ralf Jakobs
- Subjects
Gastroenterology - Published
- 2022
35. A Variational Framework for Joint Image Registration, Denoising and Edge Detection.
- Author
-
Jingfeng Han, Benjamin Berkels, Martin Rumpf, Joachim Hornegger, Marc Droske, Michael Fried, Jasmin Scorzin, and Carlo Schaller
- Published
- 2006
- Full Text
- View/download PDF
36. Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges
- Author
-
Yael R Lefkovits, Natalie Heriot, Alice Sporik, Sharnel Perera, Michael Friedlander, Cyril Dixon, Paul A Cohen, Yeh Chen Lee, Simon Hyde, Gary Richardson, Penelope Webb, Robert Rome, Madeleine King, John Zalcberg, and Penelope Schofield
- Subjects
Patient reported outcome measures ,Gynaecological cancer ,Clinical quality registry ,Ovarian cancer ,Quality of life ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract As medical treatment increasingly focuses on improving health-related quality of life, patient-reported outcome measures (PROMs) are an essential component of clinical research. The National Gynae-Oncology Registry (NGOR) is an Australian clinical quality registry. A suitable PROM was required for the NGOR ovarian cancer module to complement clinical outcomes and provide insights into outcomes important to patients. Our narrative review aimed to identify existing ovarian cancer-specific PROMs and ascertain which tool would be most appropriate for implementation into the NGOR ovarian cancer module. A literature review of Cochrane Library, Embase, MEDLINE and PubMed databases was performed to identify existing ovarian cancer-specific PROM tools. A steering committee was convened to (1) determine the purpose of, and criteria for our required PROM; and (2) to review the available tools against the criteria and recommend the most appropriate one for implementation within the NGOR. The literature review yielded five tools: MOST, EORTC QLQ-OV28, FACIT-O, NFOSI-18 and QOL-OVCA. All were developed and validated for use in clinical trials, but none had been validated for use in clinical quality registry. Our expert steering committee pre-determined purpose of a PROM tool for use within the NGOR was to enable cross-service comparison and benchmarking to drive quality improvements. They identified that while there was no ideal, pre-existing, ovarian cancer-specific PROM tool for implementation into the NGOR, on the basis of its psychometric properties, its available translations, its length and its ability to be adapted, the EORTC tool is most fit-for-purpose for integration into the NGOR. This process enabled identification of the tool most appropriate to provide insights into how ovarian cancer treatments impact patients’ quality of life and permit benchmarking across health services.
- Published
- 2024
- Full Text
- View/download PDF
37. Prognoseverbesserung durch Screening- und Surveillance-Strategien für Leber- und Pankreaserkrankungen
- Author
-
Ali Canbay, Julia Mayerle, and Michael Fried
- Published
- 2022
38. The 13 C‐methactin breath test is non‐inferior to liver biopsy in predicting liver‐related death and transplantation: A 7‐year prospective follow‐up study in 132 patients with chronic hepatitis C infection
- Author
-
Beat Müllhaupt, Achim Weber, Yaron Ilan, Oliver Goetze, Michael Fried, Wolfram Jochum, Andreas Geier, and Monika Breuer
- Subjects
Breath test ,Transplantation ,medicine.medical_specialty ,medicine.diagnostic_test ,Chronic hepatitis ,business.industry ,Internal medicine ,Liver biopsy ,medicine ,Follow up studies ,business ,Gastroenterology - Published
- 2020
39. Facingness meets mindedness
- Author
-
Michael Fried
- Subjects
Archeology ,Visual Arts and Performing Arts ,Anthropology - Published
- 2020
40. S31 The Impact of Early vs Late Biologic Initiation Among Real-World Patients With Crohn’s Disease in TARGET-IBD
- Author
-
Millie Long, Marla Dubinsky, Miguel Regueiro, Javier Zambrano, Cindy Theigs, Jenny Griffith, Wesley Matthias, Michelle Kujawski, Dolly Sharma, Robert Pearson, Julie Crawford, Laura Dalfonso, Anthony Perez, Derek Gazis, Michael Fried, Heather Morris, and David Rubin
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
41. Häufige Krankheitsbilder in der Proktologie: umfangreiche ärztliche Erfahrung vonnöten
- Author
-
Thorsten Jacobi and Michael Fried
- Published
- 2022
42. The Next Bend in the Road
- Author
-
Michael Fried
- Published
- 2010
43. Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis
- Author
-
Alexander R. Siebenhüner, Jean-Benoît Rossel, Philipp Schreiner, Matthias Butter, Thomas Greuter, Niklas Krupka, Sebastian B. U. Jordi, Luc Biedermann, Gerhard Rogler, Benjamin Misselwitz, Roland von Känel, Karim Abdelrahman, Gentiana Ademi, Patrick Aepli, Amman Thomas, Claudia Anderegg, Anca-Teodora Antonino, Eva Archanioti, Eviano Arrigoni, Nurullah Aslan, Diana Bakker de Jong, Bruno Balsiger, Mamadou-Pathé Barry, Polat Bastürk, Peter Bauerfeind, Andrea Becocci, José M. Bengoa, Janek Binek, Mirjam Blattmann, Stephan Boehm, Tujana Boldanova, Jan Borovicka, Christian P. Braegger, Stephan Brand, Francisco Bravo, Lukas Brügger, Simon Brunner, Patrick Bühr, Sabine Burk, Emanuel Burri, Sophie Buyse, Dahlia-Thao Cao, Ove Carstens, Dominique H. Criblez, Fabrizia D’Angelo, Philippe de Saussure, Lukas Degen, Joakim Delarive, Christopher Doerig, Barbara Dora, Susan Drerup, Carole Ducrey, Ali El-Wafa, Matthias Engelmann, Aude Erdmann-Voisin, Christian Felley, Markus Fliegner, Montserrat Fraga, Yannick Franc, Pascal Frei, Remus Frei, Michael Fried, Florian Froehlich, Raoul Ivano Furlano, Luca Garzoni, Martin Geyer, Marc Girardin, Delphine Golay, Ignaz Good, Ulrike Graf Bigler, Sébastien Godat, Beat Gysi, Johannes Haarer, Marcel Halama, Janine Haldemann, Pius Heer, Benjamin Heimgartner, Beat Helbling, Peter Hengstler, Denise Herzog, Cyrill Hess, Roxane Hessler, Klaas Heyland, Thomas Hinterleitner, Claudia Hirschi, Petr Hruz, Pascal Juillerat, Ioannis Kapoglou, Stephan Kayser, Céline Keller, Carolina Khalid-de Bakker, Christina Knellwolf, Christoph Knoblauch, Henrik Köhler, Rebekka Koller, Claudia Krieger, Patrizia Künzler, Rachel Kusche, Frank Serge Lehmann, Andrew Macpherson, Michel H. Maillard, Michael Manz, Maude Martinho, Rémy Meier, Christa Meyenberger, Pamela Meyer, Pierre Michetti, Bernhard Morell, Patrick Mosler, Eleni Moschouri, Christian Mottet, Christoph Müller, Beat Müllhaupt, Leilla Musso, Michaela Neagu, Cristina Nichita, Jan Niess, Andreas Nydegger, Nicole Obialo, Cassandra Oropesa, Ulrich Peter, Daniel Peternac, Laetitia Marie Petit, Valérie Pittet, Daniel Pohl, Marc Porzner, Claudia Preissler, Nadia Raschle, Ronald Rentsch, Sophie Restellini, Jean-Pierre Richterich, Sandra Riedmüller, Branislav Risti, Marc Alain Ritz, Nina Röhrich, René Roth, Vanessa Rueger, Markus Sagmeister, Gaby Saner, Riad Sarraj, Bernhard Sauter, Mikael Sawatzki, Michael Scharl, Sylvie Scharl, Martin Schelling, Susanne Schibli, Hugo Schlauri, Dominique Schluckebier, Daniela Schmid, Sybille Schmid, Jean-François Schnegg, Alain Schoepfer, Frank Seibold, Mariam Seirafi, Gian-Marco Semadeni, Arne Senning, Christiane Sokollik, Joachim Sommer, Johannes Spalinger, Holger Spangenberger, Philippe Stadler, Peter Staub, Dominic Staudenmann, Volker Stenz, Michael Steuerwald, Alex Straumann, Andreas Stulz, Michael Sulz, Michela Tempia-Caliera, Joël Thorens, Kaspar Truninger, Radu Tutuian, Patrick Urfer, Stephan Vavricka, Francesco Viani, Fabrizion Vinzens, Jürg Vögtlin, Roland Von Känel, Dominique Vouillamoz, Rachel Vulliamy, Marianne Vullièmoz, Paul Wiesel, Reiner Wiest, Stefanie Wöhrle, Bahtiyar Yilmaz, Samuel Zamora, Silvan Zander, Jonas Zeitz, Dorothee Zimmermann, University of Zurich, and Siebenhüner, Alexander R
- Subjects
medicine.medical_specialty ,mood ,610 Medicine & health ,Disease ,RC799-869 ,Hospital Anxiety and Depression Scale ,Inflammatory bowel disease ,Group B ,depressive symptoms ,inflammatory bowel disease ,Internal medicine ,medicine ,2715 Gastroenterology ,psychosocial factors ,Depression (differential diagnoses) ,Original Research ,hospital anxiety and depression scale ,business.industry ,Gastroenterology ,anti-TNF ,Diseases of the digestive system. Gastroenterology ,anxiety ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,immune-modulatory therapy ,10219 Clinic for Gastroenterology and Hepatology ,10057 Klinik für Konsiliarpsychiatrie und Psychosomatik ,Mood ,Anxiety ,medicine.symptom ,business - Abstract
Background and aims: Anxiety and depression are prevalent in patients with inflammatory bowel diseases (IBD), especially during IBD flares. IBD therapies can profoundly affect the mood of patients with IBD. We aimed to determine the long-term impact of anti-tumor necrosis factor (anti-TNF) and immunomodulators (IM) on anxiety and depressive symptoms in IBD patients. Methods: We compared three treatment groups with IM only (group A), anti-TNF ± IM (group B) and no such therapy (group C). Patients completed the hospital anxiety and depression scale (HADS) at 1 year, 3 years, and 5 years after start of treatment. Results: In total, 581 patients with IBD (42.9% Crohn’s disease, 57.1% ulcerative colitis/IBD unclassified) participated in this study. Effects of treatment were analyzed in a mixed effects model, with and without correction for confounders. Compared with group C, group B showed a significant treatment-related improvement in both anxiety and depressive symptoms within the first 2.5 years and also thereafter. Group A showed a significant long-term improvement of anxiety and both short-term and long-term improvement in depressive symptoms. The significance of these results was maintained after correction for confounders, including corticosteroid treatment. Additionally, both groups A and B showed a significant decrease in disease activity in the first 2.5 years after start of treatment and also thereafter. Anti-TNF and IM treatment were associated with a similarly significant decrease in anxiety and depressive symptoms over an observation period of up to 5 years. Conclusion: Besides a clear benefit for disease activity, anti-TNF and IM apparently improve the mood of patients with IBD.
- Published
- 2021
44. The German PCL-5: evaluating structural validity in a large-scale sample of the general German population
- Author
-
Amelie Pettrich, Michael Friedrich, Yuriy Nesterko, and Heide Glaesmer
- Subjects
Post-traumatic stress disorder ,PCL-5 ,LEC-5 ,PTSD ,psychometric properties ,factorial structure ,Psychiatry ,RC435-571 - Abstract
ABSTRACTBackground: In attempts to elucidate PTSD, recent factor analytic studies resulted in complex models with a proliferating number of factors that lack psychometrical and clinical utility. Recently, suggestions have been made to optimize factor analytic practices to meet a refined set of statistical and psychometric criteria.Objective: This study aims to assess the factorial structure of the German version of the PCL-5, implementing recent methodological advancements to address the risk of overfitting models. In doing so we diverge from traditional factor analytical research on PTSD.Method: On a large-scale sample of the German general population (n = 1625), exploratory factor analyses were run to investigate the dimensionality found within the data. Subsequently, we validated and compared all model suggestions from our preliminary analyses plus all standard and common alternative PTSD factor models (including the ICD-11 model) from previous literature with confirmatory factor analyses. We not only consider model fit indices based on WLSMV estimation but also deploy criteria such as favouring less complex models with a parsimonious number of factors, sufficient items per factor, low inter-factor correlations and number of model misspecifications.Results: All tested models showed adequate to excellent fit in respect to traditional model fit indices; however, models with two or more factors increasingly failed to meet other statistical and psychometric criteria.Conclusion: Based on the results we favour a two-factor bifactor model with a strong general PTSD factor and two less dominant specific factors – one factor with trauma-related symptoms (re-experiencing and avoidance) and one factor with global psychological symptoms (describing the trauma’s higher-order impact on mood, cognition, behaviour and arousal).From the perspective of clinical utility, we recommend the cut-off scoring method for the German version of the PCL-5. Basic psychometric properties and scale characteristics are provided.
- Published
- 2024
- Full Text
- View/download PDF
45. Food vs money? Effects of hunger on mood and behavioral reactivity to reward in anorexia nervosa
- Author
-
Sena Bluemel, Mayron Piccolo, Gabriella Milos, Michael Fried, Christoph Müller-Pfeiffer, Monique Ernst, Chantal Martin-Soelch, Sonja Schumacher, University of Zurich, and Piccolo, Mayron
- Subjects
Adult ,0301 basic medicine ,Anorexia Nervosa ,Adolescent ,Hunger ,610 Medicine & health ,030209 endocrinology & metabolism ,Satiation ,Affect (psychology) ,Body Mass Index ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Reward ,Humans ,Medicine ,Reactivity (psychology) ,General Psychology ,Physiological stress ,Meal ,030109 nutrition & dietetics ,Nutrition and Dietetics ,business.industry ,Anhedonia ,3200 General Psychology ,Fasting ,10057 Klinik für Konsiliarpsychiatrie und Psychosomatik ,10219 Clinic for Gastroenterology and Hepatology ,Mood ,Anorexia nervosa (differential diagnoses) ,2916 Nutrition and Dietetics ,Female ,medicine.symptom ,business ,psychological phenomena and processes ,Federal state ,Clinical psychology - Abstract
Background Previous studies using neuroimaging and behavioral measures reported altered reward processing in anorexia nervosa (AN). In addition, anhedonia states are frequently reported in AN, potentially due to the physiological stress produced by the permanent starvation. We investigated the effect of fasting and satiety on mood and reaction times to monetary rewards in AN patients and healthy controls. Methods Twenty-four participants with acute AN (BMI 14.4 (11.9–15.5) Kg/m2) and 17 age and gender matched healthy, normal weight subjects (HW) (BMI 21.8 (18.9–24.9) Kg/m2) performed a reward task (the wheel of fortune) involving uncertain (50/50 probability of winning high and low rewards), safe and risky (30/70 and 10/90 probabilities) categories in fasted (after an 8-h fasting period) and fed (after intake of a standardized meal) states. Data analysis was done with linear mixed models. Results AN reacted slower than HW when maximum uncertainty (50/50) was involved. Positive mood in response to winning was higher when fasting especially for HW, while negative mood in response to not winning was higher in the fed state for both groups. Still, HW were more reactive than AN to not winning a highly predictable monetary reward (10/90 safe). Conclusion The data on the reaction times indicate an impaired motor response to uncertainty in AN. Mood reactivity to winning a monetary reward does not seem to be impaired in AN, however, our results suggest that negative mood in response to not winning is less adaptive in AN. Implications to clinical psychotherapy are discussed.
- Published
- 2019
46. β6-integrin serves as a novel serum tumor marker for colorectal carcinoma
- Author
-
Philipp Busenhart, Stephan R. Vavricka, Marcel Halama, Henrik Petrowsky, Markus J. Mäkinen, Gerhard Rogler, Elisabeth Naschberger, Achim Weber, Céline Mamie, Silvia Lang, Michael Fried, Matthias Turina, Nathalie Britzen-Laurent, Pascal Frei, Anne Tuomisto, Stephanie Kasper, Jan Christoph, Eugenia Becker, Kirstin Atrott, Michael Scharl, Alexander Knuth, Lotta von Boehmer, Vera Schellerer, Michael Stürzl, Susan Bengs, Petr Hruz, Andreas Rickenbacher, Gisli Jenkins, Roland S. Croner, Marianne R. Spalinger, Dean Sheppard, and Tina Raselli
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,biology ,business.industry ,Colorectal cancer ,Integrin ,Disease ,medicine.disease ,digestive system diseases ,3. Good health ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Carcinoembryonic antigen ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,medicine ,biology.protein ,business ,Prospective cohort study ,neoplasms ,Tumor marker - Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This study aims to identify β6 -integrin (ITGB6) as a novel serum tumor marker for diagnosis, prognosis, and surveillance of CRC. ITGB6 serum levels were validated in retro- and prospective CRC patient cohorts. ITGB6 serum levels were analyzed by ELISA. Using an initial cohort of 60 CRC patients, we found that ITGB6 is present in the serum of CRC, but not in non-CRC control patients. A cut-off of ≥2 ng/mL ITGB6 reveals 100% specificity for the presence of metastatic CRC. In an enlarged study cohort of 269 CRC patients, ITGB6 predicted the onset of metastatic disease and was associated with poor prognosis. Those data were confirmed in an independent, prospective cohort consisting of 40 CRC patients. To investigate whether ITGB6 can also be used for tumor surveillance, serum ITGB6-levels were assessed in 26 CRC patients, pre- and post-surgery, as well as during follow-up visits. After complete tumor resection, ITGB6 serum levels declined completely. During follow-up, a new rise in ITGB6 serum levels indicated tumor recurrence or the onset of new metastasis as confirmed by CT scan. ITGB6 was more accurate for prognosis of advanced CRC and for tumor surveillance as the established marker carcinoembryonic antigen (CEA). Our findings identify ITGB6 as a novel serum marker for diagnosis, prognosis, and surveillance of advanced CRC. This might essentially contribute to an optimized patient care.
- Published
- 2019
47. Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): an investigation using artificial recurrent neural networks
- Author
-
Michael Fried, Breda Munoz, Jamie Wu, Kenneth Cusi, Vincent Wai-Sun Wong, Peter Mesenbrink, Marcos Pedrosa, Andrea Mospan, Miriam Vos, Rohit Loomba, and Arun Sanyal
- Subjects
Hepatology - Published
- 2022
48. Different Approaches to Piloting Advising Technology: Comparing Webster University and West Virginia State University
- Author
-
Christy McDaniel and Michael Fried
- Subjects
State (polity) ,media_common.quotation_subject ,Political science ,West virginia ,Library science ,media_common - Published
- 2021
49. Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study
- Author
-
William M, Lee, Wendy C, King, Harry L A, Janssen, Marc G, Ghany, Robert J, Fontana, Michael, Fried, Richard K, Sterling, Jordan J, Feld, Junyao, Wang, Douglas B, Mogul, Stewart L, Cooper, Adrian M Di, Bisceglie, and David, Kleiner
- Subjects
Male ,medicine.medical_specialty ,Hepatitis B virus ,viruses ,medicine.disease_cause ,Gastroenterology ,Article ,Cohort Studies ,Basal (phylogenetics) ,Hepatitis B, Chronic ,Virology ,Internal medicine ,Genotype ,medicine ,Humans ,Hepatitis B e Antigens ,Prospective Studies ,Prospective cohort study ,Aged ,Hepatitis B Surface Antigens ,Hepatology ,business.industry ,Confounding ,virus diseases ,Hepatitis B ,medicine.disease ,digestive system diseases ,Infectious Diseases ,HBeAg ,Cohort ,DNA, Viral ,North America ,Female ,business - Abstract
Hepatitis B e antigen (HBeAg) is a soluble viral protein in plasma of patients with hepatitis B virus infection. HBeAg loss is an important first stage of viral antigen clearance. We determined the rate and predictors of HBeAg loss in a North American cohort with chronic hepatitis B viral infection (CHB). Among children and adults with CHB and without HIV, HCV or HDV co-infection enrolled in the Hepatitis B Research Network prospective cohort studies, 819 were HBeAg positive at their first assessment (treatment naive or >24 weeks since treatment). Of these, 577 (200 children, 377 adults) were followed every 24-48 weeks. HBeAg loss was defined as first HBeAg-negative value; sustained HBeAg loss was defined as ≥2 consecutive HBeAg-negative values ≥24 weeks apart. During a median follow-up of 1.8 years, 164 participants experienced HBeAg loss, a rate of 11.4 (95% CI, 9.8-13.3) per 100 person-years. After adjustment for confounders, HBeAg loss rate was significantly higher in males than females, in older than younger individuals, in Whites or Blacks than Asians, in those with genotype A2 or B versus C, and in those with basal core promoter/pre-core mutations versus wild type. Additionally, during follow-up, an ALT flare and a lower quantitative HBsAg, quantitative HBeAg or HBV DNA level predicted higher rates of HBeAg loss. The majority (88%) with HBeAg loss had sustained HBeAg loss. In conclusion, a number of specific demographic, clinical and viral characteristics impacted rate of HBeAg loss and may prove useful in design and interpretation of future therapeutic studies.
- Published
- 2021
50. The Many Facets of Faculty Involvement in the Implementation Process: A Case Study of Northeast Wisconsin Technical College
- Author
-
Michael Fried and Christy McDaniel
- Subjects
Engineering management ,Engineering ,Process (engineering) ,business.industry ,business - Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.